Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Alpha-MSH (α-Melanocyte-Stimulating Hormone) peptide icon, one bubble per amino acidAlpha-MSH (α-Melanocyte-Stimulating Hormone)13 residues (approx.)SYSMEHFRWGKPVEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

Alpha-MSH (α-Melanocyte-Stimulating Hormone)

ImmuneResearch
20 min half-life·Injection·8w on / 4w off

Also known as: alpha-MSH, a-MSH, Ac-SYSMEHFRWGKPV-NH2

Over 6,500 PubMed papers back the melanocortin anti-inflammatory pathway, and two FDA-approved drugs already target it. Alpha-MSH (alpha-melanocyte-stimulating hormone) is the 13-amino-acid endogenous peptide that started it all, a POMC fragment that shuts down NF-kB signaling through MC1R activation on immune cells. The catch: a 20-minute plasma half-life makes native alpha-MSH impractical for direct clinical use. No human trial has ever tested the native form. Researchers studying melanocortin pharmacology still use it as a reference standard, but most people seeking anti-inflammatory benefits turn to KPV or synthetic analogs with better pharmacokinetics.

What Is Alpha-MSH (α-Melanocyte-Stimulating Hormone)?

Thirteen amino acids. That's the full sequence of alpha-melanocyte-stimulating hormone (alpha-MSH, Ac-SYSMEHFRWGKPV-NH2, CAS 581-05-5), a neuropeptide cleaved from proopiomelanocortin (POMC) in the pituitary, hypothalamus, and immune cells.

Alpha-MSH binds melanocortin receptors MC1R through MC5R. MC1R activation on macrophages and neutrophils blocks NF-kB nuclear translocation, cutting production of TNF-alpha, IL-1beta, IL-6, and IL-8. Catania's group mapped this pathway across 200+ references in a landmark review [1]. On melanocytes, the same MC1R signal drives melanin synthesis. In the hypothalamus, MC4R activation suppresses appetite through AgRP/NPY and POMC/CART circuits.

Preclinical data is strong. Alpha-MSH reduced inflammation in animal models of colitis, arthritis, brain ischemia, organ transplant rejection, and fibrosis. The melanocortin pathway itself is clinically validated; setmelanotide (Imcivree) won FDA approval for MC4R-related obesity, and afamelanotide (Scenesse) is approved for erythropoietic protoporphyria.

The limitation is pharmacokinetic. Native alpha-MSH degrades in roughly 20 minutes, with plasma bioavailability around 60 to 70 percent subcutaneously. Zero human clinical trials exist for the native peptide. The community skipped it entirely, moving to KPV (the C-terminal tripeptide that retains anti-inflammatory activity without pigmentation effects) or Melanotan II for tanning. Alpha-MSH remains a research-grade reference compound, not a practical therapeutic.

How Alpha-MSH (α-Melanocyte-Stimulating Hormone) Works

Alpha-MSH signals through five melanocortin receptors (MC1R through MC5R), all G-protein coupled receptors linked to stimulatory G-alpha subunits. Receptor binding activates adenylyl cyclase, raises intracellular cyclic AMP, and turns on protein kinase A (PKA).

The anti-inflammatory action centers on MC1R. When alpha-MSH binds MC1R on immune cells, it blocks NF-kB from translocating into the nucleus. NF-kB is the master switch for inflammatory gene transcription. Blocking it cuts production of TNF-alpha, IL-1beta, IL-6, IL-8, nitric oxide, and prostaglandins. At the same time, alpha-MSH pushes cells toward IL-10 secretion, an anti-inflammatory cytokine. Catania and colleagues documented these mechanisms across multiple inflammation models [1].

The immune effects go beyond cytokine suppression. Alpha-MSH inhibits neutrophil chemotaxis, reduces adhesion molecule expression (ICAM-1, VCAM-1) on endothelial cells, and suppresses T-cell proliferation. This hits inflammation at three levels: signaling, cell recruitment, and adaptive immune activation.

On melanocytes, MC1R activation stimulates tyrosinase and melanin production via MITF transcription factor upregulation. That's the pigmentation pathway, the original function scientists characterized before the anti-inflammatory story emerged.

MC4R in the hypothalamus suppresses appetite by modulating AgRP/NPY and POMC/CART neuronal circuits. Alpha-MSH also engages JAK/STAT pathway modulation, MAPK inhibition, and the cholinergic anti-inflammatory pathway. The breadth of downstream signaling explains both the therapeutic promise and the side effect profile.

Alpha-MSH (α-Melanocyte-Stimulating Hormone) Benefits

  • Alpha-MSH benefits center on anti-inflammatory signaling and melanocortin receptor activation across immune, skin, and metabolic pathways.
  • NF-kB suppression via MC1R cuts TNF-alpha, IL-1beta, IL-6, and IL-8 production in macrophages and neutrophils (Catania et al.)[3].
  • Preclinical protection in animal models of colitis, arthritis, ischemia, and heart transplant rejection, reviewed by Catania's group [1].
  • Melanogenesis and photoprotection through MC1R on melanocytes. The same pathway validated by afamelanotide (Scenesse), which has EU and Australian regulatory approval.
  • Appetite regulation via hypothalamic MC4R. Setmelanotide's FDA approval for MC4R-pathway obesity confirms this receptor target works in humans.
  • IL-10 upregulation shifts the immune balance toward resolution rather than suppression alone; KPV users report reduced gut inflammation symptoms within 2 to 4 weeks using the same pathway.
  • The C-terminal tripeptide KPV retains anti-inflammatory activity without melanogenic effects, opening a separate therapeutic window that the community has already adopted for gut inflammation.

Alpha-MSH (α-Melanocyte-Stimulating Hormone): Science vs Community Consensus

Science Only
Scientific Evidence
Moderate
Based on 5 key studies·Research only

Alpha-MSH is one of the best-characterized anti-inflammatory peptides in preclinical science.

Dosing studied: 100-500 mcg/day subcutaneous (speculative; extrapolated from preclinical data and KPV analog dosing: no human dose-finding study exists)
Read the evidence (key study, limitations)

Over 6,500 PubMed papers document its effects across dozens of inflammatory models. The melanocortin pathway is validated by two FDA-approved drugs (afamelanotide and setmelanotide). However, no human clinical trial has ever tested native alpha-MSH: all human data comes from synthetic analogs with different pharmacokinetics. A 2026 review (PMID 41825639 (opens in a new tab)) frames the melanocortin system as a neuroendocrine-immune interface with therapeutic potential far beyond current approvals, but native alpha-MSH's 20-minute half-life makes it impractical for direct clinical use.

Key Study

Catania A et al. "Targeting melanocortin receptors as a novel strategy to control inflammation" (Pharmacol Rev 2004, PMID 15001661): seminal review covering MC1R-MC5R pharmacology, anti-inflammatory mechanisms, and preclinical disease model data across 200+ references

Limitations

Zero human clinical trials on native alpha-MSH. All efficacy data is preclinical. The 20-minute half-life means animal study protocols (often using continuous infusion or IP injection) don't translate to practical human subcutaneous dosing. Approved analogs have fundamentally different PK profiles.

Community Experience
Weak
3.0/5
Based on effectively zero for native alpha-MSH. KPV community experience is growing but still small (hundreds, not thousands of reported users)

The community doesn't use native alpha-MSH.

Community dosing: No established community protocol for native alpha-MSH. KPV (the active fragment): 200-500 mcg/day SC or 500 mcg-1 mg/day oral
Read the reports (what users report 3, common issues 4)

It's been entirely replaced by KPV for anti-inflammatory purposes and by Melanotan II for tanning. People interested in melanocortin anti-inflammatory effects go straight to KPV: it's cheaper, more stable, doesn't cause pigmentation changes, and can be taken orally. Alpha-MSH discussion on forums is almost exclusively academic.

What users report (3)
  • Melanocortin pathway anti-inflammatory effects are real: but delivered via KPV or MT2, not native alpha-MSH
  • KPV users report gut inflammation relief (bloating, IBS symptoms) within 2-4 weeks
  • Tanning/photoprotection via MC1R works: but people use MT2 or afamelanotide for this, not alpha-MSH
Common issues (4)
  • Nobody has practical experience with native alpha-MSH dosing in the community
  • The 20-minute half-life makes it impractical vs. available alternatives
  • Research-grade alpha-MSH costs 5-10x more per mg than KPV
  • Source quality concerns: alpha-MSH is a niche research peptide, not a mainstream product
Science-Only Evidence

Strong preclinical science but no community adoption of native alpha-MSH. The community validated the melanocortin anti-inflammatory pathway through KPV and MT2, but skipped native alpha-MSH entirely due to its impractical pharmacokinetics. Science and community agree on the mechanism: they just disagree on which molecule to use.

Alpha-MSH (α-Melanocyte-Stimulating Hormone) Dosage Guide

SpeculativeResearch peptide; approved melanocortin agonists differ in dose and formulation
LevelDose / InjectionFrequency
Beginner100 mcg
DailyTrack
Moderate250 mcg
DailyTrack
Aggressive500 mcg
DailyTrack
Note:

Alpha-MSH is not a community peptide. It's a research reference compound, and the practical realities reflect that. Most people looking for melanocortin anti-inflammatory effects should consider KPV first; it's cheaper, more stable, and doesn't cause pigmentation.

Reconstitution math for a 1 mg vial: add 2 mL bacteriostatic water. That gives you 500 mcg/mL, or 5 mcg per unit on a 100-unit insulin syringe. A 100 mcg beginner dose is 20 units. A 250 mcg moderate dose is 50 units.

For a 5 mg vial with 2 mL BAC water: 2,500 mcg/mL, or 25 mcg per unit. A 250 mcg dose is 10 units. A 500 mcg dose is 20 units. The 5 mg vial is better value if you're running a full 8-week protocol.

Alpha-MSH degrades faster than most peptides after reconstitution. Keep it at 2 to 8 degrees Celsius and use within 14 days. Don't freeze and thaw repeatedly. If the solution goes cloudy, throw it out. Genuine alpha-MSH is sold only as a lab reagent for research; grey-market versions are rare and carry more quality risk. Research-grade product runs $80 to $250 per milligram.

Cycling Protocol

On Period
8 weeks
Off Period
4 weeks

Due to potential for melanocortin receptor desensitization with prolonged use, cycling is recommended. Monitor for skin pigmentation changes. The short half-life means effects dissipate rapidly upon discontinuation. Adjust cycle length based on research objectives and observed responses.

Calculate your Alpha-MSH (α-Melanocyte-Stimulating Hormone) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Alpha-MSH (α-Melanocyte-Stimulating Hormone) Protocols by Goal

intermediateClinical Trial8 weeks on, 4 weeks off
Loading
Wk 1-2
100 mcg · Daily · Subcutaneous
Standard
Wk 3-8
250 mcg · Daily · Subcutaneous

Expected: Reduction in inflammatory biomarkers in research models. Mild skin pigmentation changes likely. Appetite suppression possible. No human efficacy data exists for this protocol: outcomes extrapolated from preclinical models.

Monitor: Track CRP, IL-6, complete skin exam for pigmentation changes. Monitor weight and appetite. Baseline and week 4/8 labs recommended.

How to Inject Alpha-MSH (α-Melanocyte-Stimulating Hormone)

  1. 1
    Clean the vial stopper with an alcohol swab

    Draw 2 mL of bacteriostatic water into a syringe and inject it slowly down the inside wall of the vial. Don't spray directly onto the lyophilized powder.

  2. 2
    Swirl gently until dissolved

    Alpha-MSH typically reconstitutes within 2 to 3 minutes. Don't shake the vial.

  3. 3
    Using a 29 or 30 gauge insulin syringe, draw your dose

    For a 1 mg vial reconstituted with 2 mL: 20 units equals 100 mcg (beginner), 50 units equals 250 mcg (moderate). For a 5 mg vial reconstituted with 2 mL: 10 units equals 250 mcg, 20 units equals 500 mcg.

  4. 4
    Step 4

    Pinch a fold of abdominal fat, insert the needle at a 45 to 90 degree angle, and inject slowly. Rotate sites with each injection.

  5. 5
    Dose timing: morning administration is standard

    The 20-minute half-life means effects are brief; some researchers split to morning and evening dosing (8 to 12 hours apart) at the 250 mcg per injection level for the advanced protocol.

  6. 6
    Step 6

    Allow the solution to reach room temperature before injecting. Cold solution increases discomfort at the injection site.

  7. 7
    Step 7

    Store reconstituted alpha-MSH at 2 to 8 degrees Celsius, protected from light. Discard after 14 days or if the solution becomes cloudy.

Mixing your own vial? Use the Alpha-MSH (α-Melanocyte-Stimulating Hormone) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Alpha-MSH (α-Melanocyte-Stimulating Hormone) Stacking Protocols

Works With

Avoid

Melanotan II

Both activate melanocortin receptors. MT2 is a more potent, longer-lasting agonist. Combining adds no benefit and increases risk of pigmentation, nausea, and cardiovascular side effects.

Do not combine
Immunosuppressants (cyclosporine, tacrolimus, etc.)

Alpha-MSH has immunosuppressive effects (IL-10 induction, NF-kB inhibition). Adding to existing immunosuppression could compound infection risk.

Beta-blockers / antihypertensives

Animal studies show alpha-MSH can cause hypotension and bradycardia at higher doses. Combining with cardiovascular medications may amplify these effects.

Estimated Cost

Compounded
Not available: alpha-MSH is not compounded. Research-grade only: $80-250 per 1 mg as a lab reagent. Compare: KPV (3 amino acids) runs ~$30-60 per 10 mg as a research-grade product.

Pricing updated 2026-04-09

Alpha-MSH (α-Melanocyte-Stimulating Hormone) Side Effects

The most important safety concern with alpha-MSH is MC1R-driven melanocyte stimulation. Repeated dosing can cause skin darkening and hyperpigmentation. For anyone with a history of melanoma or atypical moles, this is a hard stop, not a theoretical risk. MC1R activation promotes melanocyte proliferation, and alpha-MSH is contraindicated in active or prior melanoma. A 2023 review reports both overexpressed in metastatic melanoma, and preclinical signs that the pathway helps tumors resist therapy (Dall'Olmo et al.)[2]. New or changing moles during use require immediate discontinuation and dermatologic evaluation.

Human data for native alpha-MSH is effectively zero. Every safety data point comes from preclinical models or from approved analogs (afamelanotide, setmelanotide) with different pharmacokinetic profiles. That context matters for interpreting what follows.

Appetite suppression occurs through MC4R activation in the hypothalamus. At the 250 to 500 mcg dosing range, reduced food intake is expected. Unintended weight loss exceeding 5 percent of body weight warrants stopping the protocol. Individuals with eating disorders should not use alpha-MSH.

Nausea, flushing, and fatigue have been reported in research settings. These typically appear in the first week and tend to resolve. Injecting before bed can reduce the impact of transient nausea. If nausea persists past week one, cutting the dose by 50 percent is reasonable.

Cardiovascular effects are possible at higher doses. Animal studies documented mild changes in heart rate and blood pressure. Combining alpha-MSH with beta-blockers or antihypertensives could amplify these effects; weekly blood pressure and heart rate monitoring is recommended for the first month.

Injection site reactions (redness, minor swelling) are typical for subcutaneous peptides. Rotating injection sites reduces local irritation.

The short 20-minute half-life is actually a safety feature here. Side effects clear quickly once dosing stops. Contrast that with Melanotan II, where pigmentation changes can persist for months.

Pregnancy and breastfeeding: no safety data exists. Alpha-MSH is contraindicated during pregnancy and lactation. Severe hepatic impairment may alter peptide metabolism; liver function should be assessed before starting.

Immunosuppressant users need caution. Alpha-MSH induces IL-10 and suppresses NF-kB, the same direction as cyclosporine and tacrolimus. Stacking immunosuppressive mechanisms increases infection risk.

Stop use and consult a physician for: unwanted pigmentation, persistent nausea or appetite loss affecting nutrition, any new or changing moles, unintended weight loss over 5 percent, or signs of hypersensitivity reaction.

Common Issues & Solutions

No noticeable effect after 2 weeks? The 20-minute half-life means native alpha-MSH may not reach therapeutic levels with once-daily subcutaneous dosing. Consider switching to KPV, which uses a different uptake pathway (PepT1) and doesn't have the same half-life limitation.

Unwanted skin darkening? This is MC1R activation working as expected. Reduce dose or switch to KPV, which doesn't activate melanocortin receptors and won't cause pigmentation.

Appetite gone? MC4R activation suppresses hunger. If this is unwanted, reduce dose. If appetite suppression persists after stopping, it should resolve within hours given the short half-life.

Nausea after injection? Common with melanocortin agonists, especially in the first week. Try injecting before bed. If persistent beyond week 1, reduce dose by 50%.

Peptide degrading quickly? Alpha-MSH is more fragile than most peptides. Keep reconstituted solution at 2-8C, use within 14 days max, and minimize freeze-thaw cycles. If the solution turns cloudy, discard it.

Ask AI about this page

Ask AI for a second opinion on Alpha-MSH (α-Melanocyte-Stimulating Hormone) dosing and side effects

Contraindications

  • Known hypersensitivity to alpha-MSH or POMC-derived peptides
  • Active melanoma or history of melanoma (MC1R-driven melanocyte stimulation)
  • Pregnancy or breastfeeding (insufficient safety data)
  • Severe hepatic impairment affecting peptide metabolism
  • Individuals with eating disorders (MC4R appetite suppression effects)
  • Atypical mole syndrome (dysplastic nevus syndrome) or personal/family history of melanoma: MC1R activation may promote melanocytic activity; use caution per Scenesse prescribing information

Drug Interactions

  • Melanocortin receptor antagonists (e.g., agouti-related peptide, SHU9119) may block effects
  • Immunosuppressants: additive immunomodulatory effects may increase infection risk
  • Appetite stimulants or orexigenic agents: antagonistic effects via MC4R pathway
  • Corticosteroids: overlapping anti-inflammatory mechanisms may complicate dose assessment
  • CYP-metabolized drugs: no known direct interactions, but monitor in combination studies
  • Both activate melanocortin receptors. MT2 is a more potent, longer-lasting agonist. Combining adds no benefit and increases risk of pigmentation, nausea, and cardiovascular side effects.

Product Quality

Recommended Monitoring

TestWhenTarget
CRP (C-Reactive Protein)Baseline, week 4, week 8<3.0 mg/L (normal)
IL-6Baseline and week 8 (if available)<7 pg/mL
Complete skin examBaseline, week 4, week 8, and 4 weeks post-cycleNot listed
Body weightWeeklyNot listed
Blood pressure and heart rateWeekly for the first monthNot listed
CRP (C-Reactive Protein)

Primary inflammatory marker to track anti-inflammatory response

IL-6

Alpha-MSH directly suppresses IL-6 production via NF-kB inhibition

Complete skin exam

MC1R activation promotes melanocyte activity. Monitor all moles and pigmented lesions for changes

Body weight

MC4R-mediated appetite suppression can cause unintended weight loss at higher doses

Blood pressure and heart rate

Melanocortin agonists can affect cardiovascular parameters, especially at aggressive doses

Alpha-MSH (α-Melanocyte-Stimulating Hormone) Before and After

Week 1-2

Establishment of dosing tolerance; measurable reduction in inflammatory biomarkers (CRP, IL-6) in research models

Week 3-4

Observable anti-inflammatory effects in target tissue; potential mild pigmentation changes noted

Week 5-6

Peak anti-inflammatory efficacy; sustained suppression of NF-kB-driven cytokine production

Week 7-8

Full immunomodulatory response established; assess endpoints and determine continuation or cycling off

What to Expect

Days 1 through 3: Each injection triggers rapid MC1R and MC4R activation, but proteolytic degradation limits the effect window to 30 to 60 minutes. Brief NF-kB suppression occurs per dose. Expect mild nausea, flushing, and short-lived appetite suppression that should clear within an hour or two. No community data exists for native alpha-MSH during this phase; KPV users (the closest comparison) typically report feeling nothing in the first few days.

Weeks 1 through 2: In animal models, repeated dosing begins reducing inflammatory markers like CRP and IL-6. Melanin synthesis starts ramping up in melanocytes. KPV users sometimes report mild improvement in gut symptoms by the end of week two. Nausea usually resolves. Subtle skin tone changes may start appearing. Appetite effects tend to stabilize.

Weeks 3 through 4: This is the anti-inflammatory window based on preclinical data. Animal models show peak cytokine suppression in colitis and arthritis by this point. KPV users describe reduced bloating, better stool consistency, and less joint stiffness, though results aren't dramatic for most people.

Weeks 5 through 8: Continued anti-inflammatory effect, but some animal studies flag receptor desensitization with prolonged exposure. KPV users who respond tend to plateau around weeks four through six. Pigmentation changes from MC1R activation become more apparent with native alpha-MSH. Watch for tachyphylaxis (reduced response from receptor desensitization) as a signal to cycle off.

Detailed Timeline: Science vs Community

Days 1-3
Science

Rapid MC1R/MC4R activation with each injection, but effects last only 30-60 minutes due to proteolytic degradation. Brief NF-kB suppression per dose.

Community

No community data for native alpha-MSH. KPV users report feeling nothing in the first few days.

Week 1-2
Science

In animal models, repeated dosing begins showing measurable reduction in inflammatory markers (CRP, IL-6). Melanin synthesis starts ramping up in melanocytes.

Community

KPV users (closest proxy): some report mild improvement in gut symptoms by end of week 2. Most report no obvious changes yet.

Week 3-4
Science

Peak anti-inflammatory effect in animal models. Significant cytokine suppression documented in colitis and arthritis models by this point.

Community

KPV users: clearer reports of reduced bloating, improved stool consistency, less joint stiffness. Still not dramatic for most.

Week 5-8
Science

Continued anti-inflammatory effect. Some animal studies show receptor desensitization with prolonged exposure, reducing efficacy.

Community

KPV users: those who respond tend to plateau by week 4-6. Pigmentation from alpha-MSH analogs (MT2) is well-established by this point. No equivalent data for native alpha-MSH.

Pharmacokinetics

Half-Life
20min
Bioavailability
SC: ~60-70% (limited by rapid proteolysis)
Tmax
10-15 minutes (SC)
Data Confidence
moderate

Source: Estimated ~20 minutes based on plasma clearance studies; Catania A et al., Pharmacol Rev 2004

Pharmacokinetics: Active Dose Over Time

t½ = ~20 minutes (rapid proteolytic degradation)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
13
Sequence
SYSMEHFRWGKPV
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons

Who Should Consider Alpha-MSH (α-Melanocyte-Stimulating Hormone)

  • Researchers studying inflammatory and autoimmune disease pathways
  • Scientists investigating melanocortin receptor pharmacology
  • Clinicians exploring anti-inflammatory peptide therapeutics
  • Researchers in dermatology and pigmentation biology
  • Scientists studying appetite regulation and energy homeostasis

Related Peptides

What Changed for Alpha-MSH (α-Melanocyte-Stimulating Hormone)

  1. Evidence

    Corrected Oct 12, 2026: the alpha-MSH melanoma warning now cites a 2023 review that includes preclinical data, per PubMed (PMID 37608347).

    Before: Contraindicated in active or prior melanoma (cited to PMID 20651044, an unrelated paper) After: Contraindicated in active or prior melanoma; a 2023 review reports MC1R and alpha-MSH overexpressed in metastatic melanoma (PMID 37608347)

    What this does not mean: The warning is unchanged: active or prior melanoma still rules alpha-MSH out. Only its source changed; the old citation pointed to an unrelated paper.

    Source: J Transl Med 2023, Alpha-melanocyte stimulating hormone (alpha-MSH): biology, clinical relevance and implication in melanoma (Dall'Olmo et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 8, 20265 Citations

References

  1. [1]Targeting melanocortin receptors as a novel strategy to control inflammation (Catania et al., Pharmacol Rev 2004) (opens in a new tab)PubMed (opens in a new tab)Review
  2. [2]Alpha-melanocyte stimulating hormone (alpha-MSH): biology, clinical relevance and implication in melanoma (Dall'Olmo et al., J Transl Med 2023) (opens in a new tab)PubMed (opens in a new tab)Review
  3. [3]Alpha-melanocyte-stimulating hormone: an emerging anti-inflammatory antimicrobial peptide (opens in a new tab)PubMed (opens in a new tab)Review

Related Tools

Storage & Stability

Before Reconstitution
Store at -20°C for long-term stability, up to 2 years. Protect from light.
After Reconstitution
Refrigerate at 2-8°C, use within 14 days. Aliquot to minimize freeze-thaw cycles.
Temperature
-20°C (long-term) or 2-8°C (short-term)

Frequently Asked Questions

Alpha-MSH (alpha-melanocyte-stimulating hormone) is a 13-amino-acid neuropeptide (Ac-SYSMEHFRWGKPV-NH2, CAS 581-05-5) produced by the pituitary and various immune cells. It acts on melanocortin receptors (MC1R through MC5R), mediating skin pigmentation, appetite regulation, inflammation, and immune modulation. It is the endogenous ligand that synthetic peptides like melanotan II and PT-141 are designed to mimic.

Melanotan II and PT-141 (bremelanotide) are synthetic analogs built on the alpha-MSH pharmacophore. Alpha-MSH itself has a 20-minute half-life, making it impractical for therapeutic use. The analogs were engineered with modifications (cyclization, amino acid substitutions) that extend the half-life and shift receptor selectivity toward MC4R (appetite, sexual function) or MC1R (pigmentation).

Three primary areas: (1) anti-inflammatory, where alpha-MSH suppresses NF-kB and reduces pro-inflammatory cytokines in models of colitis, arthritis, and brain injury; (2) neuroprotection, with evidence of reduced infarct size in stroke models; (3) pigmentation biology and melanoma research. Community interest centers on the anti-inflammatory mechanism.

No. Alpha-MSH itself has no FDA approval. Its derivatives have fared better: PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder, and afamelanotide (Scenesse) is approved for erythropoietic protoporphyria. The native peptide's 20-minute half-life makes it unsuitable for direct therapeutic development without structural modification.

Alpha-MSH (α-Melanocyte-Stimulating Hormone) dosing varies by experience level. Beginners typically start at 100 mcg daily, moderate users at 250 mcg daily, and aggressive protocols use 500 mcg daily.